Recce Pharmaceuticals (ASX:RCE) Debt-to-Asset : 0.04 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Recce Pharmaceuticals Debt-to-Asset?

Recce Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.12 Mil. Recce Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.08 Mil. Recce Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was A$5.47 Mil. Recce Pharmaceuticals's debt to asset for the quarter that ended in Dec. 2023 was 0.04.

Recce Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Recce Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals Debt-to-Asset Chart

Recce Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.01

0.10

Recce Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial											0.01	0.01	0.05	0.10	0.04

Competitive Comparison of Recce Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Recce Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recce Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Recce Pharmaceuticals's Debt-to-Asset falls into.

Recce Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Recce Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.148	+	0.103)	/	2.556
	=	0.10

Recce Pharmaceuticals's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.122	+	0.077)	/	5.473
	=	0.04

Recce Pharmaceuticals (ASX:RCE) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Recce Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Recce Pharmaceuticals (ASX:RCE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

R9Q:Germany

Address

180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000

Website

https://www.recce.com.au

Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. It operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat the diseases caused by various bacterias namely Sepsis, Helicobacter Pylori, Escherichia coli, Pseudomonas aeruginosa, and others.

Recce Pharmaceuticals (ASX:RCE) Headlines

No Headlines